Izraēla - angļu - Ministry of Health

teva pharmaceutical industries ltd, israel - alfacalcidol - capsules soft gelatin - alfacalcidol 0.25 mcg - alfacalcidol - - renal bone disease (renal osteodystrophy). - hypoparathyroidism. - hyperparathyroidism (with bone disease) - primary and tertiary. - rickets and osteomalacia. - osteoporosis.

Izraēla - angļu - Ministry of Health

teva pharmaceutical industries ltd, israel - alfacalcidol - capsules soft gelatin - alfacalcidol 0.25 mcg - alfacalcidol - - renal bone disease (renal osteodystrophy). - hypoparathyroidism. - hyperparathyroidism (with bone disease) - primary and tertiary. - rickets and osteomalacia. - osteoporosis.

Izraēla - angļu - Ministry of Health

teva pharmaceutical industries ltd, israel - alfacalcidol - capsules soft gelatin - alfacalcidol 0.5 mcg - - renal bone disease (renal osteodystrophy). - hypoparathyroidism. - hyperparathyroidism (with bone disease) - primary and tertiary. - rickets and osteomalacia. - osteoporosis.

Izraēla - angļu - Ministry of Health

teva pharmaceutical industries ltd, israel - alfacalcidol - capsules soft gelatin - alfacalcidol 1 mcg - alfacalcidol - - renal bone disease (renal osteodystrophy). - hypoparathyroidism. - hyperparathyroidism (with bone disease) - primary and tertiary. - rickets and osteomalacia. - osteoporosis.

Izraēla - angļu - Ministry of Health

truemed ltd, israel - migalastat as hydrochloride - hard capsule - migalastat as hydrochloride 123 mg - galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of fabry disease (α-galactosidase a deficiency) and who have an amenable mutation.

Izraēla - angļu - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 10 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. pravastatin is indicated to: 1) reduce the risk of recurrent myocardial infarction. 2)reduce the risk of undergoing myocardial revascularization procedures. 3) reduce the risk of stroke or transient ischemic attack (tia). c) hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (frederickson type iia and iib).

Izraēla - angļu - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 20 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous my

Izraēla - angļu - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 20 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. pravastatin is indicated to: 1) reduce the risk of recurrent myocardial infarction. 2)reduce the risk of undergoing myocardial revascularization procedures. 3) reduce the risk of stroke or transient ischemic attack (tia). c) hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (frederickson type iia and iib).

Izraēla - angļu - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 40 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. pravastatin is indicated to: 1) reduce the risk of recurrent myocardial infarction. 2)reduce the risk of undergoing myocardial revascularization procedures. 3) reduce the risk of stroke or transient ischemic attack (tia). c) hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (frederickson type iia and iib).

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

sel biochem xinjiang co., ltd. - tiamulin fumarate (unii: ion1q02zcx) (tiamulin - unii:e38wz4u54r) -